Hikma Pharmaceuticals (LON:HIK) Insider Mazen Darwazah Buys 315,000 Shares

Hikma Pharmaceuticals PLC (LON:HIK) insider Mazen Darwazah bought 315,000 shares of the stock in a transaction dated Thursday, November 6th. The shares were purchased at an average cost of GBX 1,601 per share, for a total transaction of £5,043,150.

Mazen Darwazah also recently made the following trade(s):

• On Tuesday, September 16th, Mazen Darwazah purchased 14,000 shares of Hikma Pharmaceuticals stock. The shares were bought at an average price of GBX 1,603 per share, with a total value of £224,420.

Hikma Pharmaceuticals Stock Up 3.1%

Shares of Hikma Pharmaceuticals stock traded up GBX 46.64 on Friday, hitting GBX 1,568.64. The company had a trading volume of 152,980,813 shares, compared to its average volume of 1,997,314. Hikma Pharmaceuticals PLC has a 1 year low of GBX 1,522 and a 1 year high of GBX 2,360. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. The stock has a 50 day moving average of GBX 1,734.94 and a 200-day moving average of GBX 1,896.07. The stock has a market capitalization of £3.47 billion, a price-to-earnings ratio of 9.39, a P/E/G ratio of 2.38 and a beta of 0.41.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Berenberg Bank reduced their price objective on Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating for the company in a research note on Thursday, October 16th. Deutsche Bank Aktiengesellschaft cut their target price on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating for the company in a research note on Tuesday, August 12th. JPMorgan Chase & Co. dropped their price objective on Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an “overweight” rating for the company in a report on Friday, August 8th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,600 price objective on shares of Hikma Pharmaceuticals in a report on Thursday, August 7th. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of GBX 2,615.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.